Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Anticoagulant Use in Patients with Chronic Renal Impairment
2005
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
1992 Standout
Mechanisms of Thrombus Formation
2008 Standout
Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients
2005
Thromboembolic Disease after Total Hip Arthroplasty
2006
Flt3 Signaling-Dependent Dendritic Cells Protect against Atherosclerosis
2011 StandoutNobel
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
2011
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
2004
The role of B cells in atherosclerosis
2018
Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
1990 Standout
Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery
2003
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
2010 StandoutNobel
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
2011
Drug-Induced Liver Injury in Humans: The Case of Ximelagatran
2009
Oral Anticoagulant Therapy
2012 Standout
New Antithrombotic Drugs
2012
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Non-Valvular Atrial Fibrillation
2006
The changing landscape of atherosclerosis
2021 StandoutNature
Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling.
1998 StandoutNobel
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
2005
A Prospective Natural-History Study of Coronary Atherosclerosis
2011 Standout
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
ENDOTHELIN: AN IMPORTANT FACTOR IN ACUTE RENAL FAILURE?
1988 StandoutNobel
Catheter-Related Thrombosis in Cancer Patients: Pathophysiology, Diagnosis, and Management
2005
The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty
2006
ALDH4A1 is an atherosclerosis auto-antigen targeted by protective antibodies
2020 Nature
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
2005
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Cardiovascular Effects of n-3 Fatty Acids
1988 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments
2004
The challenges of new drugs benefits and risks analysis: Lessons from the ximelagatran FDA Cardiovascular Advisory Committee
2006
The year in atherothrombosis
2004
Stroke
2008 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo
2001
The 2007 ABJS Nicolas Andry Award: Three Decades of Clinical, Basic, and Applied Research on Thromboembolic Disease after THA
2007
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
2003
New Anticoagulant Agents: Direct Thrombin Inhibitors
2008
Prevention of Venous Thromboembolism
2004 Standout
Antithrombotic Therapy in Atrial Fibrillation
2004
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
1988 StandoutNature
Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines
2005
Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk
2003 Standout
Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation
1990
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
2005
Atherosclerosis — An Inflammatory Disease
1999 Standout
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis
2005
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement
2005
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
2007 Standout
Prevention of Venous Thromboembolism
2008 Standout
Diesel exhaust inhalation increases thrombus formation in man
2008
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study
2003
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
2006
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study
2007
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome
2009
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
2009
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Deep vein thrombosis
2005
Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement
2003
Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
1988 Standout
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
2006
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review
2004
Hemorrhagic Complications of Anticoagulant Treatment
2004
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)
2007
Antithrombotic Therapy in Atrial Fibrillation
2008
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
1987 Standout
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Characterization of the adhesion of the human monocytic cell line U937 to cultured endothelial cells.
1985
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
2006 Standout
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
2014
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)
2011
Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration
2005
Inhibition of Endothelial Regeneration by Type-Beta Transforming Growth Factor from Platelets
1986 StandoutScience
Adaptive Response of T and B Cells in Atherosclerosis
2016
Recent advances in molecular pathology
1984
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
2003
Growth factors and the pathogenesis of atherosclerosis
1986
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
2006
Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery
2008
ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY
2005
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)
2010
Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery
2005
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes.
1987
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
2005
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
1988 StandoutScience
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Beyond Unfractionated Heparin and Warfarin
2007
Lessons From Sudden Coronary Death
2000 Standout
Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.
1986
Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit.
1986
Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury.
1994
Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary Arteries
1986 Standout
Early atherogenesis in White Carneau pigeons. I. Leukocyte margination and endothelial alterations at the celiac bifurcation.
1984
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.
1989
Plaque Rupture in Humans and Mice
2007
The biology of platelet-derived growth factor
1986 Standout
Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty
2005
The Pathogenesis of Atherosclerosis — An Update
1986 Standout
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)
2011
Vessel injury, platelet adherence, and platelet survival.
1983
Works of Anders Bylock being referenced
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial
2002
Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran
2008
Antithrombotic effects of ximelagatran plus acetylsalicylic acid (ASA) and clopidogrel plus ASA in a human ex vivo arterial thrombosis model
2006
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy
2010
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction
2005
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial
2003
Visualization of monocyte recruitment into atherosclerotic arteries using fluorescent labelling
1988
Dynamics of thrombophlebitis in central venous catheterization via basilic and cephalic veins.
1984
EARLY REACTIONS OF THE ARTERIAL WALL, FOLLOWING MECHANICAL TRAUMA
1981
A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I
2002
SURFACE ULTRASTRUCTURE OF HUMAN ARTERIES WITH SPECIAL REFERENCE TO THE EFFECTS OF SMOKING
1979
Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery
2002 StandoutNobel
Ultrastructural studies on the localization of IgG in the aortic endothelium and subendothelial intima of atherosclerotic and nonatherosclerotic rabbits
1980
Fc-dependent binding of monocytes to areas with endothelial injury in the rabbit aorta
1981
Seeding of ePTFE carotid interposition grafts in sheep and dogs: species-dependent results.
1988